Lilly and Regor Therapeutics Group Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders
- Friday, December 10, 2021, 7:00
- Finance
- Add a comment
INDIANAPOLIS and SHANGHAI, Dec. 10, 2021 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Regor Therapeutics Group have entered into a multi-year research collaboration and licensing agreement to discover, develop and commercialize novel therapies for metabolic disorders. Under the…